Search clinical trials for: Darunavir/Cobicistat

Total 277 results

Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19)

Coronavirus | Pneumonia, Pneumocystis

China
Hamad Medical Corporation

Completed

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)

Pneumonia | COVID | Coronavirus

Qatar
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants

Healthy

Japan
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
ViiV Healthcare

Completed

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

HIV-1 Infection

Spain
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

HIV-1 Infection

Spain
A.O. Ospedale Papa Giovanni XXIII
San Raffaele University Hospital, Italy

Unknown

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection (PROBE2)

HIV Infection

Italy
Janssen Scientific Affairs, LLC

Completed

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

HIV Infections | Pregnancy | HIV

United States, Puerto Rico
Therapeutic Concepts
Janssen Scientific Affairs, LLC

Unknown

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)

HIV Positive

United States
National Institutes of Health Clinical Center (CC)

Completed

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

Healthy Volunteers

United States
Stanford University
University of Colorado, Denver; Janssen Scientific Affairs, LLC

Withdrawn

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (TMC114HIV2030)

HIV/AIDS

United States
St Stephens Aids Trust
Bristol-Myers Squibb

Completed

SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat

HIV

United Kingdom
The Crofoot Research Center, Inc.
Janssen Scientific Affairs, LLC

Active, not recruiting

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) (ReSTART)

HIV-1-infection

United States
Janssen R&D Ireland

Completed

A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions

Healthy Participants

Belgium
Giovanni Di Perri

Terminated

Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) ((MARAND-X))

Hiv | Neurocognitive Dysfunction

Italy
Janssen Sciences Ireland UC

Completed

Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

Healthy

Belgium
ViiV Healthcare
Pfizer

Completed

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Healthy Subjects

United States
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection (OPTIPRIM-2)

HIV-1 Infection

France
St Stephens Aids Trust
ViiV Healthcare

Completed

The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers (SSAT073)

HIV

United Kingdom
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
East Carolina University
Janssen Scientific Affairs, LLC

Recruiting

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

HIV Infections | Obesity

United States
National Institutes of Health Clinical Center (CC)

Completed

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

HIV Infected Population With Latent Tuberculosis

United States
Janssen Sciences Ireland UC

Completed

A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants

Healthy

Netherlands
Janssen Scientific Affairs, LLC

Completed

Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

Healthy

United States
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
Fundación Pública Andaluza para la Investigación...
Merck Sharp & Dohme LLC

Unknown

Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study (ROTDIP)

HIV Infections
University Hospital, Basel, Switzerland

Terminated

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

AIDS-related Dementia Complex

Switzerland
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (PEP2)

HIV Infections

United States
Gilead Sciences

Terminated

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Chronic Hepatitis B

New Zealand, Korea, Republic of, Hong Kong, United States, Canada, Australia, Italy, India
Technical University of Munich
Gilead Sciences; MUC Research GmbH

Completed

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Insulin Resistance

Germany
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

HIV Infections

United States, Puerto Rico, Thailand, Botswana, Argentina, Brazil, Tanzania, South Africa
Sabyasachi Sen

Completed

Effect on HIV Medications on EPC Cells

AIDS

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
Gilead Sciences
Janssen Research & Development, LLC

Completed

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Juan A. Arnaiz

Unknown

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Patient Compliance | Antiretroviral Therapy Intolerance

Spain
Gilead Sciences

Completed

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

HIV Infections | Acquired Immunodeficiency Syndrome

Puerto Rico, United States, United Kingdom, Canada, Germany, Austria, Australia, Dominican Republic, Mexico
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia

United States, Israel, Spain, Australia, Netherlands, Germany, Canada, France, Italy, Lithuania
University of California, San Diego
Gilead Sciences; University at Buffalo

Completed

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

HIV

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

HIV
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy (DRV900100QD)

HIV Infections

Spain
Juan A. Arnaiz

Unknown

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir

Acquired Immune Deficiency Syndrome Virus

Spain
Massachusetts General Hospital
Gilead Sciences; Brigham and Women's Hospital

Completed

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

HIV Disease

United States
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

HIV/AIDS

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat (GHB_Cobi)

HIV | Pharmacokinetic Interactions

Spain
Community Research Initiative of New England

Completed

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors (DVD)

HIV Infections

United States
University of Zurich

Recruiting

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study

HIV Infections

Switzerland
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (DETOX)

HIV Infections

Spain
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (DATA)

HIV-1 Infection | Immunosuppression-related Infectious Disease

France

3

Subscribe